TherapeuticsMD, Inc. (NYSE MKT: TXMD), a women’s healthcare company
focused on developing and commercializing products targeted exclusively
for women, announced today that the company had been added to the 2013
Russell 3000® Index. Membership in the broad-based Russell
3000® Index also means inclusion in the Russell 2000®
and Russell Global Indexes. Annual reconstitution of Russell U.S.
Indexes captures the 4,000 largest U.S. stocks as of the end of May
2013, ranking them by total market capitalizations.
“We are pleased to note our addition to the prestigious Russell Indexes,
as it marks another significant step in the development of our company
as a leader in the women’s healthcare field,” said Robert Finizio,
Co-Founder and Chief Executive Officer. “The enhanced profile generated
by the Russell Indexes will enable us to increase awareness of
TherapeuticsMD and reach a broader investor base.”
Russell Indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. Approximately $4.1 trillion in assets are
benchmarked to the Russell Indexes.
The Russell 2000® Index is a subset of the Russell 3000®
Index representing approximately 10% of the total market capitalization
of that index. It includes approximately 2,000 of the smallest
securities based on a combination of their market cap and current index
membership. The Russell 2000® Index is constructed to provide
a comprehensive and unbiased small-cap barometer and is completely
reconstituted annually to ensure larger stocks do not distort the
performance and characteristics of the true small-cap opportunity set.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a women’s health pharmaceutical company driven
to pursue the development and commercialization of advanced hormone
replacement therapies. We are currently developing advanced hormone
therapy pharmaceutical products designed to alleviate the symptoms of
and reduce the health risks resulting from menopause-related hormone
deficiencies. We are evaluating various other potential indications for
our hormone technology, including oral contraception, preterm birth,
vulvar and vaginal atrophy, and premature ovarian failure. More
information is available at www.therapeuticsmd.com.
TherapeuticsMD® is a registered trademark.
Except for the factual information contained herein, the statement
regarding the company’s belief that the enhanced profile generated by
the Russell Indexes will enable the company to increase awareness of
TherapeuticsMD and reach a broader investor base, is a forward-looking
statement within the meaning of the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. This forward-looking
statement is subject to risks and uncertainties that may cause actual
results to differ materially, including but not limited to the actual
effect of the addition to the Russell Indexes, timely and successful
completion of clinical studies and the results thereof; challenges and
costs inherent in product marketing; the risks and uncertainties
associated with economic and market conditions; risks and uncertainties
associated with TherapeuticsMD’s business and finances in general; and
other risks detailed in TherapeuticsMD’s filings with the U.S.
Securities and Exchange Commission including its annual report on Form
10-K filed on March 12, 2013, reports on Form 10-Q and Form 8-K, and
other such filings. This forward-looking statement is based on current
information that may change. Investors are cautioned not to place undue
reliance on this forward-looking statement, which speaks only as of the
date of this press release. The forward-looking statement is qualified
in its entirety by this cautionary statement, and TherapeuticsMD
undertakes no obligation to revise or update this forward-looking
statement to reflect events or circumstances after the issuance of this
press release.
Copyright Business Wire 2013